The association of hyperuricemia and maternal and fetal outcomes among pregnant women: a meta-analysis

This meta-analysis aimed to investigate the relationship between hyperuricemia and maternal and neonatal complications in pregnant women. We searched PubMed, Embase, Web of Science, and the Cochrane Library from the databases’ inception to August 12, 2022. We included studies that reported results on the association between hyperuricemia and maternal and fetal outcomes among pregnant women. Using the random-effects model, the pooled odds ratio (OR) with 95% confidence intervals (CIs) was calculated for each outcome analysis. A total of 7 studies, including 8104 participants, were included. The pooled OR for pregnancy-induced hypertension (PIH) was 2.61 [0.26, 26.56] (<i>z</i> = 0.81, <i>p</i> = .4165; <i>I</i>² = 96.3%). The pooled OR for preterm birth was 2.52 [1.92, 3.30] (<i>z</i> = 6.64, <i>p</i> &lt; .0001; <i>I</i>² = 0%). The pooled OR for low birth weight (LBW) was 3.44 [2.52, 4.70] (<i>z</i> = 7.77, <i>p</i> &lt; .0001; <i>I</i>² = 0%). The pooled OR for small gestational age (SGA) was 1.81 [0.60, 5.46] (<i>z</i> = 1.06, <i>p</i> = .2912; <i>I</i>² = 88.6%). Results of this meta-analysis indicate a positive relationship between hyperuricemia and PIH, preterm birth, LBW, and SGA in pregnant women.